VRN 08
Alternative Names: VRN-08; VRN-081569Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Voronoi
- Class Antineoplastics
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in South Korea
- 16 Nov 2021 VRN 08 acquired by Pyramid Biosciences from Voronoi
- 10 Apr 2021 Pharmacodynamics data from preclinical trials in Breast cancer at the 112th Annual Meeting of the American Association for Cancer Research (AACR-112)